Long-term High Fat Ketogenic Diet Promotes Renal Tumor Growth in a Rat Model of Tuberous Sclerosis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liskiewicz, Arkadiusz D ^a,b   Kasprowska, Daniela ^a,c   Wojakowska, Anna ^d   Polanski, Krzysztof ^e   Lewin Kowalik, Joanna ^a   Kotulska, Katarzyna ^f   Jedrzejowska Szypulka, Halina ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c INSTITUTE OF SPORT SCIENCES   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN-LIKE GROWTH FACTOR-1, RAT; MITOGEN ACTIVATED PROTEIN KINASE; MTOR PROTEIN, RAT; OLEIC ACID; SOMATOMEDIN C; TARGET OF RAPAMYCIN KINASE;

ADVERSE EFFECTS; ANIMAL; BLOOD; CARCINOMA, RENAL CELL; DIET THERAPY; DISEASE MODEL; ENZYMOLOGY; FEMALE; KETOGENIC DIET; KIDNEY; KIDNEY NEOPLASMS; LIPID DIET; LONG EVANS RAT; MALE; METABOLISM; PATHOLOGY; TUBEROUS SCLEROSIS; TUMOR VOLUME;

ANIMALS; CARCINOMA, RENAL CELL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; INSULIN; INSULIN-LIKE GROWTH FACTOR I; KETOGENIC DIET; KIDNEY; KIDNEY NEOPLASMS; MALE; OLEIC ACID; RATS, LONG-EVANS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS; TUMOR BURDEN;

EID: 84959020604     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21807     Document Type: Article

References (60)

1. Crino, P. B., Nathanson, K. L., Henske, E. P. The tuberous sclerosis complex. N. Engl. J. Med. 28, 1345-56 (2006).
2. Franz, D. N. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics 7, 211-221 (2013).
3. Ieremia, E., Robson, A. Cutaneous PEComa: a rare entity to consider in an unusual site. Am. J. Dermatopathol. 36, 198-201 (2014).
4. Varma, S., Gupta, S., Talwar, J., Forte, F., Dhar, M. Renal epithelioid angiomyolipoma: a malignant disease. J. Nephrol. 24, 18-22 (2011).
5. Yang, P. et al. Renal cell carcinoma in tuberous sclerosis complex. Am. J. Surg. Pathol. 38, 895-909 (2014).
6. Guo, J. et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am. J. Surg. Pathol. 38, 1457-1467 (2014).
7. Bissler, J. J., Kingswood, J. C. Renal angiomyolipomata. Kidney Int. 66, 924-34 (2004).
8. Orlova, K. A., Crino, P. B. The tuberous sclerosis complex. Ann. N. Y. Acad. Sci. 1184, 87-105 (2010).
9. Wu, J. Y. et al. Magnetic source imaging localizes epileptogenic zone in children with tuberous sclerosis complex. Neurology 25, 1270-1272 (2006).
10. Curatolo, P., Bombardieri, R., Cerminara, C. Current management for epilepsy in tuberous sclerosis complex. Curr. Opin. Neurol. 19, 119-123 (2006).
11. Wang, S., Fallah, A. Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options. Neuropsychiatr. Dis. Treat. 23, 2021-30 (2014).
12. Kossoff, E. H., Henry, B. J., Cervenka, M. C. Transitioning pediatric patients receiving ketogenic diets for epilepsy into adulthood. Seizure 22, 487-489 (2013).
13. Seyfried, T. N., Flores, R., Poff, A. M., D'Agostino, D. P., Mukherjee, P. Metabolic therapy: a new paradigm for managing malignant brain cancer. Cancer Lett. 28, 289-300 (2015).
14. Allen, B. G. et al. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox Biol. 7, 963-970 (2014).
15. Kwan, H. Y. et al. Dietary lipids and adipocytes: potential therapeutic targets in cancers. J. Nutr. Biochem. 26, 303-311 (2015).
16. Khalid, S. et al. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Res. Treat. 122, 647-659 (2010).
17. VanSaun, M. N., Lee, I. K., Washington, M. K., Matrisian, L., Gorden, D. L. High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am. J. Pathol. 175, 355-364 (2009).
18. Yeung, R. S. et al. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc. Natl. Acad. Sci. USA 91, 11413-11416 (1994).
19. Kwiatkowski, D. J. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Lymphat. Res. Biol. 8, 51-57 (2010).
20. McDorman, K. S., Wolf, D. C. Use of the spontaneous Tsc2 knockout (Eker) rat model of hereditary renal cell carcinoma for the study of renal carcinogens. Toxicol. Pathol. 30, 675-680 (2002).
21. Kokubo, T. et al. Age dependence of radiation-induced renal cell carcinomas in an Eker rat model. Cancer Sci. 101, 616-623 (2010).
22. Rennebeck, G. et al. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. Proc. Natl. Acad. Sci. USA 95, 15629-15634 (1998).
23. Datta, D. et al. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J. Am. Soc. Nephrol. 19, 2437-2446 (2008).
24. Auricchio, N., Malinowska, I., Shaw, R., Manning, B. D., Kwiatkowski, D. J. Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). PLoS One 7, e31900 (2012).
25. Tannenbaum, G. S., Gurd, W., Lapointe, M. Leptin is a potent stimulator of spontaneous pulsatile growth hormone (GH) secretion and the GH response to GH-releasing hormone. Endocrinology 139, 3871-3875 (1998).
26. Wojakowska, A. et al. An optimized method of metabolite extraction from formalin-fixed paraffin-embedded tissue for GC/MS analysis. PLoS One 10, e0136902 (2015).
27. Fowelin, J., Attvall, S., von Schenck, H., Smith, U., Lager, I. Characterization of the insulin-antagonistic effect of growth hormone in insulin-dependent diabetes mellitus. Diabet Med. 12, 990-996 (1995).
28. Moller, N., Jorgensen, J. O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 30, 152-177 (2009).
29. Bielohuby, M. et al. Lack of dietary carbohydrates induces hepatic growth hormone (GH) resistance in rats. Endocrinology 152, 1948-1960 (2011).
30. Jozwiak, J., Jozwiak, S., Wlodarski, P. Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol. 9, 73-79 (2008).
31. Milder, J. B., Liang, L. P., Patel, M. Acute oxidative stress and systemic Nrf2 activation by the ketogenic diet. Neurobiol Dis. 40, 238-244 (2010).
32. Sengupta, S., Harris, C. C. p53: traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell. Biol. 6, 44-55 (2005).
33. Habib, S. L. Tuberous sclerosis complex and DNA repair. Adv. Exp. Med. Biol. 685, 84-94 (2010).
34. Hirano, T. Repair system of 7, 8-dihydro-8-oxoguanine as a defense line against carcinogenesis. J. Radiat. Res. 49, 329-40 (2008).
35. Chu-Shore, C. J., Thiele, E. A. Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet. Brain Dev. 32, 318-322 (2010).
36. Woolf, E. C., Scheck, A. C. The ketogenic diet for the treatment of malignant glioma. J. Lipid. Res. 56, 5-10 (2015).
37. Seyfried, T. N., Sanderson, T. M., El-Abbadi, M. M., McGowan, R., Mukherjee, P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br. J. Cancer. 89, 1375-1382 (2003).
38. Zhou, W. et al. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr. Metab. (Lond). 21, 4-5 (2007).
39. Seyfried, T. N., Marsh, J., Shelton, L. M., Huysentruyt, L. C., Mukherjee, P. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Epilepsy Res. 100, 310-326 (2012).
40. Freedland, S. J. et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 68, 11-19 (2008).
41. Mavropoulos, J. C. et al. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev. Res. (Phila.) 2, 557-565 (2009).
42. Caso, J. et al. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate 73, 449-454 (2013).
43. Lv, M., Zhu, X., Wang, H., Wang, F., Guan, W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS One 9, e115147 (2014).
44. Poff, A. M., Ari, C., Seyfried, T. N., D'Agostino, D. P. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One 8, e65522 (2013).
45. Otto, C. et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 8,122 (2008).
46. Stafford, P. et al. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr. Metab. (Lond.) 7, 74 (2010).
47. Abdelwahab, M. G. et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One 7, e36197 (2012).
48. Kiebish, M. A., Han, X., Cheng, H., Chuang, J. H., Seyfried, T. N. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J. Lipid. Res. 49, 2545-2556 (2008).
49. Vollmers, H. P. et al. Characterization of four new gastric cancer cell lines. Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 63, 335-343 (1993).
50. Sawayama, H. et al. Clinical impact of the Warburg effect in gastrointestinal cancer. Int. J. Oncol. 45, 1345-1354 (2014).
51. Szatmári, T. et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 97, 546-553 (2006).
52. Soto-Guzman, A., Robledo, T., Lopez-Perez, M., Salazar, E. P. Oleic acid induces ERK1/2 activation and AP-1 DNA binding activity through a mechanism involving Src kinase and EGFR transactivation in breast cancer cells. Mol. Cell Endocrinol. 294, 81-91 (2008).
53. Liu, Z. et al. Effects of oleic acid on cell proliferation through an integrin-linked kinase signaling pathway in 786-O renal cell carcinoma cells. Oncol Lett. 5, 1395-1399 (2013).
54. Carter-Su, C., Schwartz, J., Smit, L. S. Molecular mechanism of growth hormone action. Annu. Rev. Physiol. 58, 187-207 (1996).
55. Zhu, T., Ling, L., Lobie, P. E. Identification of a JAK2-independent pathway regulating growth hormone (GH)-stimulated p44/42 mitogen-activated protein kinase activity. GH activation of Ral and phospholipase D is Src-dependent. J. Biol. Chem. 277, 45592-45603 (2002).
56. Anjum, R., Blenis, J. The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 9, 747-758 (2008).
57. Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77-85 (2005).
58. Mackenzie, M., Baracos, V. E. Cancer-associated cachexia: altered metabolism of protein and amino acids in Metabolic and therapeutic aspects of amino acids in clinical nutrition 2nd edn (ed Cynober, l. A.), 339-354 (Boca Raton: CRC Press, 2004).
59. Berlett, B. S., Stadtman, E. R. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272, 20313-6 (1997).
60. Chatterjee, A., Mambo, E., Osada, M., Upadhyay, S., Sidransky, D. The effect of p53-RNAi and p53 knockout on human 8-oxoguanine DNA glycosylase (hOgg1) activity. FASEB J. 20, 112-114 (2006).